Brii Bio completes HK$0.09 million on-market buyback; treasury shares rise to 13.48 million

Bulletin Express10-14

Brii Biosciences Limited (Brii Bio) disclosed that it repurchased 110,000 ordinary shares on 14 October 2026 through the Hong Kong Stock Exchange. The shares were bought at prices ranging between HK$0.83 and HK$0.8538, for a total consideration of HK$0.09 million.

Following the transaction, the number of issued shares (excluding treasury shares) fell marginally by 0.015 % to 721.84 million, while treasury shares increased to 13.48 million. The company’s overall share count remained unchanged at 735.32 million.

The buyback was executed under the repurchase mandate approved on 16 June 2026, which authorises the repurchase of up to 72.19 million shares. Including this latest purchase, Brii Bio has repurchased 758,000 shares under the mandate—equivalent to 0.105 % of the issued share base on the approval date.

Under Hong Kong Listing Rules, Brii Bio faces a 30-day moratorium on new share issues or treasury share sales until 13 November 2026 following the repurchase. The company confirmed that all transactions were conducted in compliance with the exchange’s regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment